Enlarged vestibular aqueduct (EVA) is a malformation associated with sensorineural hearing loss in children. Mutations in the SLC26A4. gene are also associated with EVA and may contribute to more severe hearing losses that progress, but the timescale of this progression remains unknown. Given that children undergo significant speech and language development, a better understanding of the timing and extent of hearing loss is needed for individuals who have EVA. Through a retrospective review of records in a local database, we aimed to 1) estimate the prevalence of a SLC26A4 mutation in this pediatric EVA cohort; and 2) compare hearing threshold severity and timing of progression across children who have EVA and different SLC26A4 statuses. Of 62 children with EVA, 39 had available genetic results and of these, 15 had at least one mutation of the SLC26A4 gene (38%). The children with a SLC26A4 mutation had a more severe onset of hearing loss and a more rapid progression of hearing loss over time, especially for higher frequencies, than children without a mutation in this gene. This longitudinal information may facilitate prognostic counseling to pediatric patients and better inform the audiology follow-up appointments for these families.

The authors have declared no competing interest.

This stidu was funded by the American Academy of Audiology (Jerry Northern Scholarship in Pediatric Audiology to M.O.) and the Minnesota Lions Foundation Research Grant (H.H.).

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Institutional Review Board approval of the University of Minnesota and Fairview Health Systems Research gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

The data of this study are available on reasonable request from the corresponding author.